Myriad Genetics Statistics
Total Valuation
Myriad Genetics has a market cap or net worth of $338.12 million. The enterprise value is $425.22 million.
Important Dates
The last earnings date was Tuesday, May 5, 2026, after market close.
| Earnings Date | May 5, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Myriad Genetics has 94.45 million shares outstanding. The number of shares has increased by 2.42% in one year.
| Current Share Class | 94.45M |
| Shares Outstanding | 94.45M |
| Shares Change (YoY) | +2.42% |
| Shares Change (QoQ) | +0.43% |
| Owned by Insiders (%) | 3.90% |
| Owned by Institutions (%) | 83.34% |
| Float | 78.66M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 28.46 |
| PS Ratio | 0.41 |
| Forward PS | 0.38 |
| PB Ratio | 1.00 |
| P/TBV Ratio | 2.34 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 140.89 |
| PEG Ratio | 0.73 |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 0.51 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.40, with a Debt / Equity ratio of 0.63.
| Current Ratio | 2.40 |
| Quick Ratio | 1.91 |
| Debt / Equity | 0.63 |
| Debt / EBITDA | 51.90 |
| Debt / FCF | n/a |
| Interest Coverage | -4.64 |
Financial Efficiency
Return on equity (ROE) is -76.73% and return on invested capital (ROIC) is -15.04%.
| Return on Equity (ROE) | -76.73% |
| Return on Assets (ROA) | -4.77% |
| Return on Invested Capital (ROIC) | -15.04% |
| Return on Capital Employed (ROCE) | -11.79% |
| Weighted Average Cost of Capital (WACC) | 10.72% |
| Revenue Per Employee | $307,037 |
| Profits Per Employee | -$148,111 |
| Employee Count | 2,700 |
| Asset Turnover | 0.99 |
| Inventory Turnover | 8.86 |
Taxes
In the past 12 months, Myriad Genetics has paid $100,000 in taxes.
| Income Tax | 100,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -6.77% in the last 52 weeks. The beta is 1.81, so Myriad Genetics's price volatility has been higher than the market average.
| Beta (5Y) | 1.81 |
| 52-Week Price Change | -6.77% |
| 50-Day Moving Average | 4.64 |
| 200-Day Moving Average | 6.03 |
| Relative Strength Index (RSI) | 29.67 |
| Average Volume (20 Days) | 1,618,774 |
Short Selling Information
The latest short interest is 7.88 million, so 8.35% of the outstanding shares have been sold short.
| Short Interest | 7.88M |
| Short Previous Month | 8.24M |
| Short % of Shares Out | 8.35% |
| Short % of Float | 10.02% |
| Short Ratio (days to cover) | 7.70 |
Income Statement
In the last 12 months, Myriad Genetics had revenue of $829.00 million and -$399.90 million in losses. Loss per share was -$4.29.
| Revenue | 829.00M |
| Gross Profit | 580.00M |
| Operating Income | -64.10M |
| Pretax Income | -399.80M |
| Net Income | -399.90M |
| EBITDA | -12.30M |
| EBIT | -64.10M |
| Loss Per Share | -$4.29 |
Full Income StatementBalance Sheet
The company has $124.40 million in cash and $211.50 million in debt, with a net cash position of -$87.10 million or -$0.92 per share.
| Cash & Cash Equivalents | 124.40M |
| Total Debt | 211.50M |
| Net Cash | -87.10M |
| Net Cash Per Share | -$0.92 |
| Equity (Book Value) | 337.40M |
| Book Value Per Share | 3.57 |
| Working Capital | 182.60M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $2.40 million and capital expenditures -$15.70 million, giving a free cash flow of -$13.30 million.
| Operating Cash Flow | 2.40M |
| Capital Expenditures | -15.70M |
| Depreciation & Amortization | 51.80M |
| Net Borrowing | 65.00M |
| Free Cash Flow | -13.30M |
| FCF Per Share | -$0.14 |
Full Cash Flow StatementMargins
Gross margin is 69.96%, with operating and profit margins of -7.73% and -48.24%.
| Gross Margin | 69.96% |
| Operating Margin | -7.73% |
| Pretax Margin | -48.23% |
| Profit Margin | -48.24% |
| EBITDA Margin | -1.48% |
| EBIT Margin | -7.73% |
| FCF Margin | n/a |
Dividends & Yields
Myriad Genetics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -2.42% |
| Shareholder Yield | -2.42% |
| Earnings Yield | -118.27% |
| FCF Yield | -3.93% |
Analyst Forecast
The average price target for Myriad Genetics is $6.25, which is 90.78% higher than the current price. The consensus rating is "Hold".
| Price Target | $6.25 |
| Price Target Difference | 90.78% |
| Analyst Consensus | Hold |
| Analyst Count | 10 |
| Revenue Growth Forecast (5Y) | 5.99% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on March 26, 2009. It was a forward split with a ratio of 2:1.
| Last Split Date | Mar 26, 2009 |
| Split Type | Forward |
| Split Ratio | 2:1 |
Scores
Myriad Genetics has an Altman Z-Score of -0.15 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -0.15 |
| Piotroski F-Score | 4 |
